ANDAORALTROCHE/LOZENGE
Approved
Oct 2012
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NICOTINE POLACRILEX (nicotine polacrilex) by Design Pharmaceuticals. Approved for cholinergic nicotinic agonist [epc]. First approved in 2012.
Mechanism of Action
Pharmacologic Class:
Cholinergic Nicotinic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on NICOTINE POLACRILEX at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.